Skip to main content
Dx & Vx Co., Ltd. logo

Dx & Vx Co., Ltd. — Investor Relations & Filings

Ticker · 180400 ISIN · KR7180400004 KO Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-09-16 AGM Information
Country KR South Korea
Listing KO 180400

About Dx & Vx Co., Ltd.

https://www.dxvx.com/

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Recent filings

Filing Released Lang Actions
주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for DXVX, detailing the date, location, and agenda items (such as the appointment of a director). This type of document is a standard proxy solicitation or meeting notice sent to shareholders to inform them of upcoming votes, which falls under the Proxy Solicitation & Information Statement category.
2025-09-16 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given it is a regulatory disclosure regarding corporate governance and meeting preparation, it fits best under the general regulatory filing category.
2025-09-16 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service of South Korea. It details the finalization of a corporate asset transfer (disposal of shares in Hanmi Science) by DXVX. Since this document reports the completion of a specific corporate transaction (M&A/Asset disposal), it falls under the M&A Activity category.
2025-08-29 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (DXVX) regarding a 'Single Sale/Supply Contract' amendment. It details a change in the contract period and provides specific financial terms of a supply agreement. Since this is a specific regulatory disclosure regarding a material contract update that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2025-08-14 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is titled '반기보고서' (Semi-annual Report) for the company '디엑스앤브이엑스' (Dx&Vx Co., Ltd.) for the period covering January 1, 2025, to June 30, 2025. It contains detailed corporate information, business descriptions, history, capital changes, and governance details, which are characteristic of a comprehensive interim financial report. It is not an announcement of a report (RPA) or a simple regulatory filing (RNS), as it provides substantive financial and operational data for the specified period. H1 2025
2025-08-14 Korean
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from a Korean exchange (KRX) regarding the confirmation of audit results and financial status (specifically capital impairment). It provides specific financial data for the semi-annual period ending 2025-06-30. While it contains financial data, it is a specific regulatory disclosure form required by the exchange for companies facing capital impairment or audit issues, rather than a full interim report or a simple announcement of a report. Given the nature of the disclosure (regulatory compliance regarding financial health), 'RNS' (Regulatory Filings) is the most appropriate classification. H1 2025
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.